News

Artiva Biotherapeutics Welcomes Dr. Alison Moore to Leadership Team

Artiva Biotherapeutics Welcomes Dr. Alison Moore to Leadership Team

Artiva Biotherapeutics Strengthens Board with New Appointment

Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) is making notable strides in the biotech landscape by announcing the appointment of Alison Moore, Ph.D., to its Board of Directors. Dr. Moore, bringing with her over 20 years of experience in the biotechnology and pharmaceutical sectors, is currently the Chief Technical Officer of Codexis Inc. (NASDAQ: CDXS). Her extensive background and expertise will undoubtedly contribute positively to Artiva’s mission.

Dr. Moore's Impressive Background

Before her role at Codexis, Dr. Moore served as the CTO of Allogene Therapeutics and held a significant position at Amgen, where she was the Senior Vice President of Process Development. Her career has been marked by a focus on cell therapy manufacturing, making her a key asset as Artiva develops its lead program, AlloNK®. This therapy aims to address unmet medical needs in patients suffering from autoimmune diseases and forms of cancer.

Artiva's Commitment to Innovation

At Artiva, CEO Fred Aslan, M.D. expressed strong confidence in Dr. Moore's ability to leverage her expertise in allogenic cell therapies to enhance the company's clinical pipeline. This is particularly important as AlloNK® is currently in clinical trials targeting systemic lupus erythematosus and other autoimmune indications. The therapy’s scalable manufacturing process is already gaining attention in clinical studies.

AlloNK®: A Game Changer in Therapy

AlloNK® represents a groundbreaking advancement in the field of cell therapy. As an allogeneic, non-genetically modified NK cell therapy candidate, it has garnered interest for its potential to fulfill the needs of patients with various conditions, providing hope for more effective treatment options.

The Strategic Forward Path

This strategic board appointment aligns with Artiva's goal of distinguishing itself in the competitive landscape of allogeneic cell therapies. The company was established in 2019 and operates under a productive partnership with GC Cell, which provides exclusive access to its manufacturing technology outside certain regions. This partnership allows Artiva to enhance its operational capabilities and speed up the delivery of its therapies to patients.

The Bigger Picture for Codexis

In related industry developments, Codexis is also undergoing significant transitions, with its former CFO, Sriram Ryali, stepping down. The company has reported positive Q2 2024 revenues amounting to $8 million, which is buoyed by strong forecasts of double-digit growth in product revenues driven by its pharmaceutical manufacturing innovations.

Market Performance and Future Outlook

Despite facing challenges, such as a 38.59% decline in revenue year-over-year, Codexis has demonstrated resilience, showcasing a remarkable 93.53% total return to investors over the past year. This context may positively influence perceptions of both Codexis and Artiva, especially as Dr. Moore steps into her new role.

Frequently Asked Questions

What is the significance of Dr. Alison Moore's appointment at Artiva?

Dr. Alison Moore's extensive experience in biotech, particularly in cell therapies, is expected to enhance Artiva's clinical pipeline and advancements in their therapeutic offerings.

What is AlloNK® and its current status?

AlloNK® is an allogeneic NK cell therapy candidate in clinical trials for autoimmune diseases, including systemic lupus erythematosus, showcasing promising potential for various indications.

How does Artiva's partnership with GC Cell benefit its operations?

This partnership grants Artiva exclusive rights to GC Cell's NK cell manufacturing technology, allowing for streamlined processes and accelerated therapy delivery to patients.

What changes are happening at Codexis?

Codexis has seen leadership changes, with a new CTO and CFO appointed amidst ongoing efforts to bolster its financial standing and strategic direction, despite some revenue decline.

What are the implications of the biotech industry's current challenges?

The biotech industry continually faces volatility, and companies must navigate financial hurdles while innovating. However, successes like Artiva's new appointments can positively influence investor confidence and market presence.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 83

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
DKSH's Vietnam Oncology Pact Carries Real Promise, Risk

Updated Category News Views 58

A cancer-market announcement ought to make investors pause before they reach for a spreadsheet. Specialised Therapeutics and DKSH have signed an exclusive partnership to bring oncology therapies into Vietnam, and the human case is painfully clear: the country recorded an estimated 180,000 new cancer cases and more than 120,000 deaths annually in the 2022 GLOBOCAN data....

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 45

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 318

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 394

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 140

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 661

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 570

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Australia Leads TTW's 2027 Global Travel Country List

Updated Category News Views 43

A travel ranking is a map, not a balance sheet, and that distinction matters more than the glossy numbering. TTW has put Australia at the head of its editorial list of the 50 best countries to visit in 2027, followed by Switzerland, Japan, Canada and Thailand. Fair enough. Those are formidable tourism brands with the scenery, infrastructure and cultural pull to back up...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 265

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading

Top 5 Most Recently Viewed Articles

Realty ONE Group Wins Prestigious Tech100 Award for Innovation

Updated Category News Views 367

Realty ONE Group Receives HousingWire's 2025 Tech100 Award Realty ONE Group International, a leading lifestyle brand and one of the most rapidly expanding franchises in the real estate sector, has been recognized with the esteemed HousingWire's 2025 Tech100 Real Estate award. This award spotlights groundbreaking companies making strides in the industry. Innovative...

Continue Reading
Conifex Timber Inc. Plans Q4 2024 Results Call Announcement

Updated Category News Views 271

Conifex Timber Inc. Plans for Q4 2024 Results Conference Call Conifex Timber Inc. (TSX: CFF) is gearing up for an important event as it approaches the release of its fourth quarter 2024 financial results. Set to occur after the market closes, this significant announcement is slated for March 12, 2025. Following the release, a conference call has been scheduled for March...

Continue Reading
FASTSIGNS® Achieves Top Spot for Veterans Franchise Recognition

Updated Category News Views 214

FASTSIGNS® Earns Top Ranking for Franchise Opportunities for Veterans Leading recognition highlights commitment to supporting veterans in business. FASTSIGNS®, a prominent name in signs, graphics, and visual communications, has once again made waves by being named one of the top franchises for veterans, securing the fifth position out of 150. This acknowledgment by a...

Continue Reading
Krispy Kreme Investors Alerted to Class Action Lawsuit Opportunity

Updated Category News Views 209

Krispy Kreme's Class Action Lawsuit: What Investors Need to Know Levi & Korsinsky, LLP has taken an important step to inform investors regarding a class action securities lawsuit involving Krispy Kreme, Inc. (NASDAQ: DNUT). This legal action aims to represent shareholders who may have suffered losses due to alleged securities fraud. Understanding the Nature of the Class...

Continue Reading
Christina Lake Cannabis Delays Annual Financial Statements Until July

Updated Category News Views 212

Christina Lake Cannabis Faces Delays in Financial Filings Christina Lake Cannabis Corp. (CSE: CLC) has recently announced a significant delay in the filing of its annual financial statements. The company indicated that it will be unable to submit these critical documents, which include management's discussion and analysis along with the required certifications from its...

Continue Reading